Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 27

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 27
---
, including limitations on our ability to incur liens or additional debt, pay dividends,
repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt
financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise
additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials.
We may also be required to sell or license to other parties rights to develop or commercialize our drug candidate that we would prefer
to retain.

See “Risk
Factors” included herein and in our 2024 Annual Report on Form 10-K for fiscal 2024 filed with the Securities and Exchange
Commission (the “SEC”) on March 28, 2025 for additional discussion of risks associated with our capital
requirements.

Cash Flows for the Three Months Ended March
31, 2025 and 2024

The following table shows
a summary of our cash flows for the three months ended March 31, 2025 and 2024.

    For the Three Months Ended March 31, 

    2025  
    2024 
  
    Net cash flows from operating activities 
    $(1,063,041) 
    $(65,165)
  
    Net cash flows from investing activities 
     -  
     - 
  
    Net cash flows from financing activities 
    $-  
    $45,000 
  
    Net increase (decrease) in cash 
    $(1,063,041) 
    $(35,953)

Net Cash Flows From Operating
Activities:

Net cash used in operating
activities during the three months ended March 31, 2025 was $1,063,041, as compared to net cash used in operating activities of $65,165.
The increase in net cash used in operating activities was primarily related to the changes in our net loss.

Net Cash Flows From Investing
Activities:

No net cash was provided by
or used in investing activities for the three months ended March 31, 2025 and 2024.

Net Cash Flows From Financing Activities:

Net cash provided in financing
activities during the three months ended March 31, 2025 was $0, as compared to net cash provided in financing activities of $45,000. The
decrease in net cash provided was primarily related to no